Integrating molecular diagnostics into anticancer drug discovery

被引：0

作者：

István Peták

Richárd Schwab

László Őrfi

László Kopper

György Kéri

机构：

[1] István Peták is at KPS Medical Biotechnology and Healthcare Services Ltd,and the Ist Department of Pathology and Experimental Cancer Research

[2] 5 Ribary,and the Department of Pharmaceutical Chemistry

[3] 1022 Budapest,László Kopper is at the Ist Department of Pathology and Experimental Cancer Research

[4] Hungary,Department of Medical Chemistry and Pathobiochemistry

[5] Semmelweis University,undefined

[6] 26 Üllői út,undefined

[7] 1085 Budapest,undefined

[8] Hungary.,undefined

[9] Richárd Schwab is at KPS Medical Biotechnology and Healthcare Services Ltd,undefined

[10] 5 Ribary,undefined

[11] 1022 Budapest,undefined

[12] Hungary.,undefined

[13] László Őrfi is at Vichem Chemie Research Ltd,undefined

[14] Budapest,undefined

[15] Hungary,undefined

[16] Semmelweis University,undefined

[17] Högyes E. u. 9.,undefined

[18] 1092 Budapest,undefined

[19] Hungary.,undefined

[20] Semmelweis University,undefined

[21] 26 Üllői út,undefined

[22] 1085 Budapest,undefined

[23] Hungary.,undefined

[24] György Kéri is at Vichem Chemie Research Ltd,undefined

[25] Budapest,undefined

[26] Hungary,undefined

[27] and the Pathobiochemistry Research Group of the Hungarian Academy of Sciences,undefined

[28] Semmelweis University,undefined

[29] Budapest,undefined

[30] H-1085,undefined

[31] Hungary.,undefined

来源：

Nature Reviews Drug Discovery | 2010年 / 9卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Efforts to repeat the success of pioneering molecularly targeted cancer drugs, such as trastuzumab, for particular patient populations have been hampered by factors such as a lack of correlation between the molecular markers used to select patients for treatment and the drug response. This article highlights lessons learned from the development of drugs targeting members of the epidermal growth factor receptor family, and discusses strategies to decrease the risk of failure in clinical trials by more effectively integrating molecular diagnostics into anticancer drug discovery and development.

引用

页码：523 / 535

页数：12

共 50 条

[31] Integrating bacterial molecular genetics with chemical biology for renewed antibacterial drug discovery
Parkhill, Susannah L.
Johnson, Eachan O.
BIOCHEMICAL JOURNAL, 2024, 481 (13) : 839 - 864
[32] Integrating expression profiling into drug discovery
Ulrich, RG
FASEB JOURNAL, 2006, 20 (05): : A888 - A888
[33] Colorimetric sensors for drug discovery and biomedical diagnostics
Jelinek, R
DRUG DEVELOPMENT RESEARCH, 2000, 50 (3-4) : 497 - 501
[34] Fruit fly for anticancer drug discovery and repurposing
Nainu, Firzan
Salim, Emil
As'ad, Muh. Fadhil
Chandran, Deepak
Dhama, Kuldeep
Rabaan, Ali A.
Emran, Talha B.
ANNALS OF MEDICINE AND SURGERY, 2023, 85 (02): : 337 - 342
[35] Anticancer drug discovery and pharmaceutical chemistry: A history
Braña M.F.
Sánchez-Migallón A.
Clinical and Translational Oncology, 2006, 8 (10) : 717 - 728
[36] Plant Metabolomics: The Future of Anticancer Drug Discovery
Dabbousy, Ranin
Rima, Mohamad
Roufayel, Rabih
Rahal, Mohamad
Legros, Christian
Sabatier, Jean-Marc
Fajloun, Ziad
PHARMACEUTICALS, 2024, 17 (10)
[37] Topoisomerase as target for antibacterial and anticancer drug discovery
Kathiravan, Muthu K.
Khilare, Madhavi M.
Nikoomanesh, Kiana
Chothe, Aparna S.
Jain, Kishor S.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2013, 28 (03) : 419 - 435
[38] The evolution of anticancer drug discovery from plants
Howes, Melanie-Jayne R.
LANCET ONCOLOGY, 2018, 19 (03): : 293 - 294
[39] Discovery and development of novel anticancer drug capecitabine
Ishitsuka, H
Shimma, N
Horii, I
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1999, 119 (12): : 881 - 897
[40] Heterocyclic Compounds: Importance in Anticancer Drug Discovery
Kumar, Naresh
Goel, Nidhi
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (19) : 3196 - 3207

← 1 2 3 4 5 →